作者
Ofri Mosenzon, Stephen D Wiviott, Hiddo JL Heerspink, Jamie P Dwyer, Avivit Cahn, Erica L Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A Murphy, Thomas A Zelniker, Ingrid AM Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A Johansson, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John PH Wilding, Marc S Sabatine, Itamar Raz
发表日期
2021/8/1
期刊
Diabetes Care
卷号
44
期号
8
页码范围
1805-1815
出版商
American Diabetes Association
简介
OBJECTIVE
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial, which included populations with lower cardiorenal risk.
RESEARCH DESIGN AND METHODS
DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes, creatinine clearance >60 mL/min, and either atherosclerotic cardiovascular disease (CVD; 40.6%) or risk-factors for CVD (59.4%) to dapagliflozin or placebo. Urinary albumin-to-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and yearly thereafter. The change in UACR over time was measured as a continuous and categorical variable (≤15, >15 to <30, ≥30 to ≤300, and >300 mg/g) by treatment arm. The composite cardiorenal outcome was a …
学术搜索中的文章
O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer… - Diabetes Care, 2021